To include your compound in the COVID-19 Resource Center, submit it here.

Biomarkers

TECHNOLOGY: Tissue markers

Counts of F. nucleatum bacteria in tumor mucosae could help predict responses to oxaliplatin and Xeloda combination therapy in colorectal cancer patients. In 31 patients,

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE